Metacrine Inc. (MTCR): Price and Financial Metrics
GET POWR RATINGS... FREE!
MTCR Stock Price Chart Interactive Chart >
MTCR Price/Volume Stats
| Current price | $0.41 | 52-week high | $1.73 |
| Prev. close | $0.41 | 52-week low | $0.30 |
| Day low | $0.40 | Volume | 36,000 |
| Day high | $0.41 | Avg. volume | 987,646 |
| 50-day MA | $0.43 | Dividend yield | N/A |
| 200-day MA | $0.48 | Market Cap | 17.33M |
Metacrine Inc. (MTCR) Company Bio
Metacrine, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery and development of differentiated therapies for patients with liver and gastrointestinal diseases. Its farnesoid X receptor, or FXR, is central to modulating liver and GI diseases. The company was founded by Ronald M. Evans, Richard A. Heyman, and Michael Downes in 2014 and is headquartered in San Diego, CA.
Latest MTCR News From Around the Web
Below are the latest news stories about METACRINE INC that investors may wish to consider to help them evaluate MTCR as an investment opportunity.
Is Metacrine Inc. (MTCR) a opportunity to investors?In Tuesday’s session, Metacrine Inc. (NASDAQ:MTCR) marked $0.46 per share, up from $0.42 in the previous session. While Metacrine Inc. has overperformed by 8.43%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MTCR fell by -63.85%, with highs and lows ranging from $1.73 to $0.30, whereas […] |
Metacrine Reports Third-Quarter 2022 ResultsSAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. “We made great progress during the quarter in advancing our proposed merger with Equillium,” said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. “We believe that Equillium has demonstrated compelling clinical d |
Can you still get a good price for Metacrine Inc. (MTCR) Shares at this point?As of Tuesday, Metacrine Inc.’s (NASDAQ:MTCR) stock closed at $0.50, up from $0.42 the previous day. While Metacrine Inc. has overperformed by 18.45%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MTCR fell by -86.80%, with highs and lows ranging from $4.12 to $0.35, whereas the […] |
Why Is Equillium (EQ) Stock Soaring 20% Today?Biotech firm Equillium is on the move as it released positive data for a lupus therapeutic, though EQ stock has a tough road ahead. |
Analysts Say That Metacrine Inc. (NASDAQ:MTCR) Is Likely To Make It To $0.50 In 12 MonthsIn last trading session, Metacrine Inc. (NASDAQ:MTCR) saw 0.36 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $0.43 trading at -$0.03 or -7.35% at ring of the bell on the day assigns it a market valuation of $18.80M. That closing price of MTCR’s stock is at … Analysts Say That Metacrine Inc. (NASDAQ:MTCR) Is Likely To Make It To $0.50 In 12 Months Read More » |
MTCR Price Returns
| 1-mo | 1.96% |
| 3-mo | -10.38% |
| 6-mo | -13.52% |
| 1-year | -68.22% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -39.19% |
| 2021 | -91.42% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...